Abstract
Treatment with psychotropic medication may sometimes be jeopardised because of the COVID-19 pandemic. One underlying reason is the lack of COVID-19-specific psychopharmacology guidelines. Here, we discuss five considerations arising from our clinical experience and pharmacological background knowledge to enable safe and well-informed psychopharmacotherapy during the COVID-19 pandemic.
Original language | English |
---|---|
Pages (from-to) | 471-474 |
Number of pages | 4 |
Journal | The British journal of psychiatry : the journal of mental science |
Volume | 217 |
Issue number | 3 |
DOIs | |
Publication status | Published - 1 Sept 2020 |
Keywords
- COVID-19
- epidemiology
- prescribing
- psychiatry
- psychopharmacology